Improving medicine through innovative science
Geneuity Clinical Research Services has partnered with the clinical and research community for a decade. We are a leader in the integration of molecular diagnostics and pathology testing for pharma, clinical research organizations, and medical device companies. We are experienced in outsourced specialty testing and device validation and our expert clinical and scientific staff provide a consultative approach to protocol review and biomarker selection.
Geneuity Clinical Research Services is a provider of outsourced specialty laboratory testing services for clinical studies and assay validation. We support small pharma, biotechnology, contract research organizations, central laboratories, and medical device companies.
Geneuity is a private company able to integrate with your development team. We employ the latest molecular and cellular technologies to support and integrate with our anatomic pathology data, and applying bioinformatics, provide timely actionable data to help you make faster, better informed decisions. We provide personalized services for studies of a few samples to those involving thousands of specimens.
We specialize in molecular and cellular testing for phase I to phase III as well as assay and companion diagnostic validation. Geneuity’s experience and expertise working within a GCLP environment, delivers quality operations, data integrity, and expert protocol collaboration. Geneuity is a division of Molecular Pathology Laboratory Network, Inc (MPLN), a CLIA certified high complexity laboratory, accredited by ISO 15189 and College of American Pathologists (CAP).
Board certified professionals in molecular diagnostics, cytogenetics, and hematopathology are available to assist the development and review of study protocols, and provide technical and interpretive expertise as well as consultation.
Results of the study with the blood test Epi proColon® is now published in the journal of “Cancer Treatment and Research Communications” . Epigenomics AG announced that the results of the ADMIT study confirm that […]
Geneuity Clinical Research Services, was one of three laboratories supporting the PRESEPT (Prospective Evaluation of Septin9 Performance for Colorectal Cancer Screening) clinical trial (1,2,3). The ‘Donald Payne Sr. Colorectal Cancer Detection Act of 2016″ was […]
Geneuity a subsidiary of Molecular Pathology Laboratory Network Inc. launches Ventana PD-L1 and PD-1 assays, expanding their oncology immunohistochemistry menu of tests for NSCLC and other tumor types. MPLN’s repertoire of integrated testing now includes […]
